autologous cd19/cd22 car t cells
Cell therapyexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2025 (NCT06709469)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Leukemia, Lymphoid · Phase 1/Phase 2
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Phase 1
- Lymphoma · Phase 1
- Lymphoma, B-Cell · Phase 1/Phase 2
- Lymphoma, Large-Cell, Immunoblastic · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
Mechanism of action
- CD22Immunity, passive
CD22 immunity, passive
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07162571 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2026 | Belarusian State Medical University |
| NCT07166419 | Phase 1 | Dec 1, 2025 | Ohio State University |
| NCT06709469 | Phase 1 | Jun 1, 2025 | Universidad Autonoma de Madrid |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Belarusian State Medical University | Academic/Hospital | 1 | 1 | 1 | 2026 |
| Ohio State University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Universidad Autonoma de Madrid | Academic/Hospital | 1 | 1 | 1 | 2025 |
3 organizations
Page 1 / 1